Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary


Syndax Pharmaceuticals is owned by 125.60% institutional investors, 1.69% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.41% of SNDX shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.88% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals125.60%1.69%-27.29%
SectorHealthcare Stocks 50.53%12.40%37.07%
IndustryBiotech Stocks 48.96%12.12%38.92%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.02M10.41%$197.18M
Kynam capital management, lp8.05M9.29%$175.99M
Blackrock7.91M9.28%$162.33M
Vanguard group6.23M7.19%$130.90M
Goldman sachs group5.86M6.77%$128.13M
State street5.66M6.53%$123.69M
Bank of america corp /de/4.05M4.67%$88.43M
Vanguard capital management3.93M4.53%$85.86M
Deerfield management company, l.p. (series c)3.78M4.36%$82.63M
Adage capital partners gp3.31M3.84%$50.95M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp8.05M9.73%$175.99M
Aisling capital management lp1.32M6.10%$28.79M
Kingdon capital management2.50M5.60%$54.65M
Knott david m jr437.25K5.05%$9.56M
Catalio capital management, lp1.22M4.99%$26.58M
Prosight management, lp1.20M4.52%$26.23M
Lion point capital, lp36.00K3.76%$786.96K
Eversept partners, lp2.80M3.17%$61.17M
Sphera funds management1.01M2.89%$22.18M
Silverarc capital management1.21M2.76%$26.55M

Top Buyers

HolderShares% AssetsChange
Adage capital partners gp3.31M0.08%1.88M
Millennium management2.05M0.02%1.85M
State street5.66M0.00%1.23M
Vanguard group6.23M0.00%1.09M
Loomis sayles & co l p923.62K0.03%923.62K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---2.27M
Point72 asset management---1.99M
Bvf inc/il---1.88M
Balyasny asset management126.14K0.00%-1.69M
Sofinnova investments---1.52M

New Positions

HolderShares% AssetsChangeValue
Loomis sayles & co l p923.62K0.03%923.62K$20.19M
Sixth street partners management company814.30K0.00%814.30K$17.80M
First trust advisors lp456.70K0.01%456.70K$9.98M
Jupiter asset management366.57K0.04%366.57K$8.01M
Ikarian capital333.73K0.52%333.73K$5.13M

Sold Out

HolderChange
Tfc financial management-1.00
Quadrant capital group-3.00
Jpl wealth management-5.00
Nelson, van denburg & campbell wealth management group-13.00
Bare financial services-23.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026251-3.46%108,796,3309.49%1250.95%133-6.99%7710.00%
Mar 31, 202694-61.94%15,133,904-84.85%170.13%45-62.18%23-70.13%
Dec 31, 2025166-32.52%53,238,549-47.45%610.45%78-39.06%46-34.29%
Sep 30, 20252385.78%101,267,9708.78%1171.01%1236.03%6913.11%
Jun 30, 2025232-101,730,1911.68%1170.86%116-3.33%651.56%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF3.46M3.88%7.95K
Vanguard Health Care Inv2.99M3.50%-
Vanguard Total Stock Mkt Idx Inv2.83M3.19%14.81K
Vanguard Morn Total Stk Mkt Idx Investor2.83M3.19%14.81K
Vanguard MStar Total Stk Mkt Idx Invest2.84M3.18%14.88K
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
iShares Russell 2000 ETF2.27M2.54%-40.22K
SPDR® S&P Biotech ETF1.54M1.78%3.43K
Eventide Healthcare & Life Sciences I1.24M1.40%249.06K
Hood River Small-Cap Growth Instl1.21M1.36%-

Recent Insider Transactions


DateNameRoleActivityValue
Jul 08, 2026Metzger Michael A Chief Executive OfficerSell$784.78K
Jun 12, 2026Botwood Nicholas A.J. Head of R&D, CMOSell$566.60K
Jun 11, 2026Botwood Nicholas A.J. Head of R&D, CMOSell$617.04K
Jun 01, 2026Goldan Keith A. Chief Financial OfficerSell$22.35K
Jun 01, 2026Metzger Michael A Chief Executive OfficerSell$130.02K

Insider Transactions Trends


DateBuySell
2026 Q3-1
2026 Q2-4
2026 Q1-4
2025 Q4--
2025 Q3-6

SNDX Ownership FAQ


Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 125.60%, followed by 1.69% insiders and -27.29% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 48.96%, which Syndax Pharmaceuticals exceeds.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (9.02M shares, 10.41%), Kynam capital management, lp (8.05M shares, 9.29%), and Blackrock (7.91M shares, 9.28%). Together, they hold 28.99% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.73% of its assets in 8.05M Syndax Pharmaceuticals shares, valued at 175.99M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.88% of its total shares outstanding invested in 3.46M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools